Identification and characterisation of new class of PI3K modulators in oncology

Project description

PI3K signalling activation as an anti-cancer strategy

Phosphoinositide 3-kinase (PI3K) signalling is central for many biological functions and exhibits aberrant regulation in cancer. The EU-funded PI3K MODULATORS project aims to hyper-activate PI3K signalling in white blood cells as a therapeutic intervention for haematological malignancies. For this purpose, researchers will undertake a high-throughput screening approach to discover small-molecule PI3K activators specific for the white blood cell isoform of PI3K. They will study the mode of action of these activators as well as the mechanism of PI3K-mediated cancer cell death through various structural and biochemical analyses. The project's results will pave the way for the exploitation of PI3K drugs in cancer therapy.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › earth and related environmental sciences › geology › mineralogy › crystallography
• natural sciences › biological sciences › biochemistry › biomolecules › lipids
• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › molecular biology › structural biology

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

UNIVERSITY COLLEGE LONDON

Net EU contribution

€ 212 933,76

Address

Gower Street
WC1E 6BT London
United Kingdom

Region

London › Inner London — West › Camden and City of London

Activity type

Higher or Secondary Education Establishments

Links

Other funding

€ 0,00